One concrete data point for the thread. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.
Following on from Dr.SportsMedIN — and this may be the naive question:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
Dr.NateNeph said:Worth knowing that the injection site changes very little.
Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.
My Lp(a) has remained at 72 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.NateNeph said:Worth knowing that the injection site changes very little.
CRP reduction on cardiovascular risk — this is the lab result that excites me most:
Baseline hsCRP: 8.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 3.5 mg/L (moderate risk)
Month 12 hsCRP: 0.4 mg/L (low risk)
This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 15% to 6%. My cardiologist is genuinely impressed.
Dr.NateNeph said:Worth knowing that the injection site changes very little.
Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.